Healthcare Quarterly Reports and Event - Research Report on Hologic, Akorn, Synta, PDL, and Exact Sciences

 Healthcare Quarterly Reports and Event - Research Report on Hologic, Akorn,
                        Synta, PDL, and Exact Sciences

PR Newswire

NEW YORK, November 4, 2013

NEW YORK, November 4, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Hologic
Inc. (NASDAQ: HOLX), Akorn, Inc. (NASDAQ: AKRX), Synta Pharmaceuticals Corp.
(NASDAQ: SNTA), PDL BioPharma, Inc. (NASDAQ: PDLI), and Exact Sciences
Corporation (NASDAQ: EXAS). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Hologic Inc. Research Report

On October 24, 2013, Hologic Inc. (Hologic) announced that it intends to
release its Q4 FY 2014 results on Monday, November 11, 2013, after market
close. Hologic reported that it will also host its Q4 FY 2014 conference call
on the same day at 5:00 p.m. ET. The Company stated that the live webcast is
accessible through its Investor Relations website, and the replay of the
webcast will be available two hours after the completion of the call. The Full
Research Report on Hologic Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/d132_HOLX]

Akorn, Inc. Research Report

On October 25, 2013, Akorn, Inc. (Akorn) announced its participation during
the upcoming American Academy of Ophthalmology 2013 in New Orleans, LA. Akorn
reported that it will be located at booth # 2838, from Saturday, November 16,
2013 to Tuesday, November 19, 2013. The Full Research Report on Akorn, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/900c_AKRX]

Synta Pharmaceuticals Corp. Research Report

On October 29, 2013, Synta Pharmaceuticals Corp. (Synta) announced that it
will release its Q3 2013 results on Monday, November 4, 2013, before market
open. Synta reported that the release will be followed by its Q3 2013
conference call at 10:00 a.m. ET. The Company further informed that the live
webcast is accessible through its Investor Relations website, while the
archived webcast will be available under the Webcasts and Events section on
its Investor Relations website. The Full Research Report on Synta
Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/8ecc_SNTA]

PDL BioPharma, Inc. Research Report

On October 28, 2013, PDL BioPharma, Inc. (PDL) announced that it will release
its Q3 2013 results on Wednesday, November 6, 2013, after market close. PDL
reported that it will host its Q3 2013 conference call on the same day at 4:30
p.m. ET. The Company further informed that the live webcast and replay will be
available under the Events and Presentations section on its website. The Full
Research Report on PDL BioPharma, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.AnalystsCorner.com/r/full_research_report/066b_PDLI]

Exact Sciences Corporation Research Report

On October 29, 2013, Exact Sciences Corporation (Exact Sciences) released its
Q3 2013 results with total revenues of $1.0 million, which were flat as
compared to Q3 2012. The Company posted a net loss of $11.2 million in Q3
2013, compared to a net loss of $13.0 million in Q3 2012. Exact Sciences
reported diluted loss per share of $0.16 in Q3 2013, compared to diluted loss
per share of $0.21 in Q3 2012. Kevin T. Conroy, President and CEO, Exact
Sciences, said, "As Cologuard moves through the FDA approval process, we also
are focused on commercial readiness and operational excellence." Conroy
continued, "The combination of Cologuard and our service that will make it
easy for physicians to order and patients to use our test is a powerful one.
We believe that this combination will increase the colorectal cancer screening
rate and positively impact patient health." The Full Research Report on Exact
Sciences Corporation - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/9c49_EXAS]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to making mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com/

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.